Full Text Articles in Oncology & Cancer

1Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of the benefit of involved node radiotherapyAnnals of Oncology, October 08, 2012  Full Text  Clinical Article
2Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphomaAnnals of Oncology, October 08, 2012  Full Text
3Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, 3, in Patients with Metastatic MelanomaClinical Cancer Research, October 08, 2012  Full Text  Clinical Article
4A Phase I Dose Esclation Study of Tivantinib in Adult Pts w Metastatic Solid TumorsClinical Cancer Research, October 08, 2012  Full Text  Clinical Article
5Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258)-an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors-in Patients with Advanced MelanomaClinical Cancer Research, October 08, 2012  Full Text  Clinical Article
6Repeated and Aggressive Pulmonary Resections for Leiomyosarcoma Metastases Extends SurvivalAnnals of Thoracic Surgery, October 08, 2012  Full Text
7HIV envelope-mediated, CCR5/α4β7-dependent killing of CD4-negative γδ T cells which are lost during progression to AIDSBlood, October 08, 2012  Full Text
8Pam50 breast cancer subtyping by RT-QPCR and concordance with standard clinical molecular markersBMC Genomics, October 08, 2012  Full Text
9Breast vibro-acoustography: initial results show promiseBreast Cancer Research, October 08, 2012  Full Text
10Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomesBreast Cancer Research, October 08, 2012  Full Text
1NCCN publishes new guidelines for smoking cessation, effort led by Ohio State oncologistThe OSUCCC–James, March 31, 2015
2How to get smarter on pills for seniorsThomas Jefferson University News, March 31, 2015
3Genetic background determines whether aspirin/NSAIDS will reduce colorectal cancer riskMassachusetts General Hospital, March 31, 2015
4Study suggests precision medicine for adrenal cancerUniversity of Michigan Health System, March 31, 2015
5Findings help unravel lung cancer drug resistanceBroad Institute News, March 31, 2015
6Blood thinning drug helps in understanding a natural HIV barrierUniversity of East Anglia News, March 31, 2015
7Study bolsters "turbocharged" protein as a promising tool in hemophiliaThe Children's Hospital of Philadelphia, March 31, 2015
8Miriam Hospital researchers find topical tranexamic acid use in primary hip and knee arthroplasty reduces blood transfusion ratesThe Miriam Hospital, March 31, 2015
9New Tobacco Atlas details scale, harms of tobacco epidemicAmerican Cancer Society News, March 31, 2015
10Bright new hope for beating deadly hereditary stomach and breast cancersUniversity of Otago News, March 31, 2015

Show Me:

Cisplatin monotherapy effective in pediatric high-risk hepatoblastoma

As reported in the Journal of Pediatric Hematology/Oncology, treatment of children with high-risk hepatoblastoma (n=14) with cisplatin monotherapy was as effective as cisplatin + doxorubicin combination therapy, but with less toxicity. The complete resection rate was 78.6%, the event-free survival rate was 81.8%, and the OS rate was 100%.

CTC count predicts survival in mBC

As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).

Increased incidence of second primary cancers in patients with salivary gland tumors

As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocMHC class I-restricted melanoma peptide vaccines are not effective in treating metastatic melanoma patients.

Clinical Pearl from Smartest DocSubstituting other protein sources for red meat in the adolescent diet may decrease premenopausal breast cancer risk.

Clinical Pearl from Smartest DocSingle nucleotide polymorphisms are associated with tumor presence and aggressiveness in clear cell renal carcinoma.

Be Ready for Upcoming 2015 Board Exams!

Be prepared for board reviews with confidence with 1000s of board exam style questions. Prepare Here